Morgan Stanley analyst Jeffrey Hung lowered the firm’s price target on Exelixis to $21 from $22 and keeps an Equal Weight rating on the shares. The firm issued its biotechnology Q1 sector preview, stating that broadly for the group it does not "expect many surprises" given recently issued guidance. The firm sees investor focus being mainly on Q2 catalysts in the space.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- Exelixis (NASDAQ:EXEL) Faces a Proxy Battle; Analysts Remain Bullish
- Exelixis responds to Farallon Capital Management
- Exelixis holder Farallon issues letter on nominees for director candidates
- Biotech Alert: Searches spiking for these stocks today
- Jefferies says ‘activist has a point’ on Exelixis R&D
Questions or Comments about the article? Write to editor@tipranks.com